Iron chelation adherence to deferoxamine and deferasirox in thalassemia
β Scribed by Felicia Trachtenberg; Elliott Vichinsky; Dru Haines; Zahra Pakbaz; Lauren Mednick; Amy Sobota; Janet Kwiatkowski; Alexis A. Thompson; John Porter; Thomas Coates; Patricia J. Giardina; Nancy Olivieri; Robert Yamashita; Ellis J. Neufeld; for the Thalassemia Clinical Research Network
- Publisher
- John Wiley and Sons
- Year
- 2011
- Tongue
- English
- Weight
- 124 KB
- Volume
- 86
- Category
- Article
- ISSN
- 0361-8609
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
Pepe et al.: A T2\* MRI prospective survey on heart iron in thalassemia major patients treated with deferasirox versus deferiprone and desferrioxamine in monotherapy.
## Background Trials of iron chelator regimens have increased the treatment options for cardiac siderosis in beta-thalassemia major (TM) patients. Treatment effects with improved left ventricular (LV) ejection fraction (EF) have been observed in patients without overt heart failure, but it is uncle
The livers of 30 cases of thalassemia (19//j-thal/HbE, seven thal/HbH and four /J-thai major) were studied histopathologically and electron microscopically, in an effort to define the morphologic alterations due to iron overload. The results of light and electron microscopy were similar in most case